~~<i id='1BA3D12DED'><strike id='1BA3D12DED'><tt id='1BA3D12DED'><pre id='1BA3D12DED'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

focus

author：entertainment 2025-09-30 00:46:44 - browse：16

JOHNSON & JOHNSON HEADQUARTERS — Daniel Hulshizer/AP

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the company’s research and development efforts.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Congress likely to miss an opportunity to fix drug shortages issue

hotspot

leisure time

focus

entertainment

hotspot

LeeKlafczynskiforSTATWASHINGTON—Congressisconsideringamust-passpandemicpreparednessbillthatpresentsa

WSS

Manchin plays down potential 3rd

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

ER docs worry over extreme heat as a 'mass casualty event'

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

Care demand spikes challenge UnitedHealth’s provider arm

Biden administration sends mixed signals on US soldier who crossed into North Korea

knowledge

focus

hotspot

The high cost of giving birth even with insurance

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Argenx drug significantly slows progression of nerve disorder

Medicare details structure of new drug price negotiation program

The new HIV moral panic

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Global childhood vaccinations edge closer to pre

At least 13 dead in Texas as scorching temps continue

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

leisure time

Europe sees delivery challenges ahead on Alzheimer's therapies

Does aspartame cause cancer? What new WHO guidance says

Twill hunts for pharma partner to market its depression app

Georgia court denies Trump's request to quash DA's 2020 election probe

FDA seeking to stop procedures at two unregulated stem cell clinics

15 die by electrocution after transformer explodes in northern India

focus

entertainment

entertainment

hotspot